RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CANTALE O
Collezione AOU San Luigi di Orbassano

Items : 6

Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2025 Jan;205:104540. doi: 10.1016/j.critrevonc.2024.104540. Epub 2024 Oct 30

2025
AOU San Luigi di Orbassano

Nepote A; Poletto S; Bertaglia V; Carnio S; Piumatti C; Lanzetta C; Cantale O; Saba G; Bironzo P; Novello S; Tralongo AC;

A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study. in ESMO open / ESMO Open. 2024 Jul;9(7):103624. doi: 10.1016/j.esmoop.2024.103624. Epub 2024 Jun 28.

2024
AOU San Luigi di Orbassano

Avancini A; Giannarelli D; Borsati A; Carnio S; Cantale O; Nepote A; Mangiapane F; Bafunno D; Galetta D; Longo V; Tregnago D; Trestini I; Belluomini L; Sposito M; Insolda J; Schena F; Milella M; Novello S; Pilotto S;

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. in International immunopharmacology / Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28.

2022
AOU San Luigi di Orbassano

Banna GL; Cantale O; Muthuramalingam S; Cave J; Comins C; Cortellini A; Addeo A; Signori A; McKenzie H; Escriu C; Barone G; Chan S; Hicks A; Bainbridge H; Pinato DJ; Ottensmeier C; Gomes F;

International Survey on Frailty Assessment in Patients with Cancer. in The oncologist / Oncologist. 2022 Oct 1;27(10):e796-e803. doi: 10.1093/oncolo/oyac133.

2022
AOU San Luigi di Orbassano

Banna GL; Cantale O; Haydock MM; Battisti NML; Bambury K; Musolino N; O'Carroll E; Maltese G; Garetto L; Addeo A; Gomes F;

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.

2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May

2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...